Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 126 entries
Sorted by: Best Match Show Resources per page
Salvage treatments in Hodgkin's disease.

European journal of cancer (Oxford, England : 1990)

Bonadonna G.
PMID: 1828957
Eur J Cancer. 1991;27(5):530-1. doi: 10.1016/0277-5379(91)90208-u.

No abstract available.

Cite
Bonadonna G. Salvage treatments in Hodgkin's disease. Eur J Cancer. 1991;27(5):530-1doi: 10.1016/0277-5379(91)90208-u.
Bonadonna, G. (1991). Salvage treatments in Hodgkin's disease. European journal of cancer (Oxford, England : 1990), 27(5), 530-1. https://doi.org/10.1016/0277-5379(91)90208-u
Bonadonna, G. "Salvage treatments in Hodgkin's disease." European journal of cancer (Oxford, England : 1990) vol. 27,5 (1991): 530-1. doi: https://doi.org/10.1016/0277-5379(91)90208-u
Bonadonna G. Salvage treatments in Hodgkin's disease. Eur J Cancer. 1991;27(5):530-1. doi: 10.1016/0277-5379(91)90208-u. PMID: 1828957.
Copy Download .nbib Format: NLM
Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America.

Clinical and translational allergy

Torres MJ, Romano A, Celik G, Demoly P, Khan DA, Macy E, Park M, Blumenthal K, Aberer W, Castells M, Barbaud A, Mayorga C, Bonadonna P.
PMID: 28293415
Clin Transl Allergy. 2017 Mar 13;7:7. doi: 10.1186/s13601-017-0144-0. eCollection 2017.

Drug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous allergic reactions. DHR evaluations are frequently needed in...

Cite
Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clin Transl Allergy. 2017;7:7doi: 10.1186/s13601-017-0144-0.
Torres, M. J., Romano, A., Celik, G., Demoly, P., Khan, D. A., Macy, E., Park, M., Blumenthal, K., Aberer, W., Castells, M., Barbaud, A., Mayorga, C., & Bonadonna, P. (2017). Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clinical and translational allergy, 77. https://doi.org/10.1186/s13601-017-0144-0
Torres, M J, et al. "Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America." Clinical and translational allergy vol. 7 (2017): 7. doi: https://doi.org/10.1186/s13601-017-0144-0
Torres MJ, Romano A, Celik G, Demoly P, Khan DA, Macy E, Park M, Blumenthal K, Aberer W, Castells M, Barbaud A, Mayorga C, Bonadonna P. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clin Transl Allergy. 2017 Mar 13;7:7. doi: 10.1186/s13601-017-0144-0. eCollection 2017. PMID: 28293415; PMCID: PMC5347172.
Copy Download .nbib Format: NLM
Homing in pelagic birds: a pilot experiment with white-chinned petrels released in the open sea.

Behavioural processes

Benhamou S, Bried J, Bonadonna F, Jouventin P.
PMID: 12543487
Behav Processes. 2003 Feb 28;61(1):95-100. doi: 10.1016/s0376-6357(02)00168-7.

During the breeding period white-chinned petrels (Procellaria aequinoctialis) repeatedly perform long foraging trips in the open ocean from their breeding island, and are able to home with an astonishing precision. The orientation mechanisms involved are not yet known. By...

Cite
Benhamou S, Bried J, Bonadonna F, et al. Homing in pelagic birds: a pilot experiment with white-chinned petrels released in the open sea. Behav Processes. 2003;61(1):95-100doi: 10.1016/s0376-6357(02)00168-7.
Benhamou, S., Bried, J., Bonadonna, F., & Jouventin, P. (2003). Homing in pelagic birds: a pilot experiment with white-chinned petrels released in the open sea. Behavioural processes, 61(1), 95-100. https://doi.org/10.1016/s0376-6357(02)00168-7
Benhamou, Simon, et al. "Homing in pelagic birds: a pilot experiment with white-chinned petrels released in the open sea." Behavioural processes vol. 61,1 (2003): 95-100. doi: https://doi.org/10.1016/s0376-6357(02)00168-7
Benhamou S, Bried J, Bonadonna F, Jouventin P. Homing in pelagic birds: a pilot experiment with white-chinned petrels released in the open sea. Behav Processes. 2003 Feb 28;61(1):95-100. doi: 10.1016/s0376-6357(02)00168-7. PMID: 12543487.
Copy Download .nbib Format: NLM
Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors.

Pharmacology, biochemistry, and behavior

Powell GL, Bonadonna JP, Vannan A, Xu K, Mach RH, Luedtke RR, Neisewander JL.
PMID: 29807065
Pharmacol Biochem Behav. 2018 Aug;171:46-53. doi: 10.1016/j.pbb.2018.05.015. Epub 2018 May 25.

AIMS: The dopamine D3 receptor (D3R) is a pharmacotherapeutic target for drug dependence. We have successfully imaged human D3Rs using radiolabeled LS-3-134, an arylamide phenylpiperazine with moderate selectivity for the D3R over D2R and low efficacy at the D2...

Cite
Powell GL, Bonadonna JP, Vannan A, et al. Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. Pharmacol Biochem Behav. 2018;171:46-53doi: 10.1016/j.pbb.2018.05.015.
Powell, G. L., Bonadonna, J. P., Vannan, A., Xu, K., Mach, R. H., Luedtke, R. R., & Neisewander, J. L. (2018). Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. Pharmacology, biochemistry, and behavior, 17146-53. https://doi.org/10.1016/j.pbb.2018.05.015
Powell, Gregory L, et al. "Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors." Pharmacology, biochemistry, and behavior vol. 171 (2018): 46-53. doi: https://doi.org/10.1016/j.pbb.2018.05.015
Powell GL, Bonadonna JP, Vannan A, Xu K, Mach RH, Luedtke RR, Neisewander JL. Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. Pharmacol Biochem Behav. 2018 Aug;171:46-53. doi: 10.1016/j.pbb.2018.05.015. Epub 2018 May 25. PMID: 29807065.
Copy Download .nbib Format: NLM
Hermite regularization of the lattice Boltzmann method for open source computational aeroacoustics.

The Journal of the Acoustical Society of America

Brogi F, Malaspinas O, Chopard B, Bonadonna C.
PMID: 29092578
J Acoust Soc Am. 2017 Oct;142(4):2332. doi: 10.1121/1.5006900.

The lattice Boltzmann method (LBM) is emerging as a powerful engineering tool for aeroacoustic computations. However, the LBM has been shown to present accuracy and stability issues in the medium-low Mach number range, which is of interest for aeroacoustic...

Cite
Brogi F, Malaspinas O, Chopard B, et al. Hermite regularization of the lattice Boltzmann method for open source computational aeroacoustics. J Acoust Soc Am. 2017;142(4):2332doi: 10.1121/1.5006900.
Brogi, F., Malaspinas, O., Chopard, B., & Bonadonna, C. (2017). Hermite regularization of the lattice Boltzmann method for open source computational aeroacoustics. The Journal of the Acoustical Society of America, 142(4), 2332. https://doi.org/10.1121/1.5006900
Brogi, F, et al. "Hermite regularization of the lattice Boltzmann method for open source computational aeroacoustics." The Journal of the Acoustical Society of America vol. 142,4 (2017): 2332. doi: https://doi.org/10.1121/1.5006900
Brogi F, Malaspinas O, Chopard B, Bonadonna C. Hermite regularization of the lattice Boltzmann method for open source computational aeroacoustics. J Acoust Soc Am. 2017 Oct;142(4):2332. doi: 10.1121/1.5006900. PMID: 29092578.
Copy Download .nbib Format: NLM
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a .

Therapeutic advances in medical oncology

Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassineti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, Petrelli F.
PMID: 32010236
Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020.

BACKGROUND: The risk of venous thromboembolic events (VTE) during adjuvant chemotherapy for colorectal cancer (CRC) is unknown. We aim to evaluate if the Khorana score (KS) can predict this risk, and if it represents a prognostic factor for overall...

Cite
Barni S, Rosati G, Lonardi S, et al. Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a . Ther Adv Med Oncol. 2020;12:1758835919899850doi: 10.1177/1758835919899850.
Barni, S., Rosati, G., Lonardi, S., Pella, N., Banzi, M., Zampino, M. G., Dotti, K. F., Rimassa, L., Marchetti, P., Maiello, E., Artioli, F., Ferrari, D., Labianca, R., Bidoli, P., Zaniboni, A., Sobrero, A., Iaffaioli, V., De Placido, S., Frassineti, G. L., Ciarlo, A., Buonadonna, A., Silvestris, N., Piazza, E., Pavesi, L., Moroni, M., Clerico, M., Aglietta, M., Giordani, P., Galli, F., Galli, F., & Petrelli, F. (2020). Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a . Therapeutic advances in medical oncology, 121758835919899850. https://doi.org/10.1177/1758835919899850
Barni, Sandro, et al. "Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a ." Therapeutic advances in medical oncology vol. 12 (2020): 1758835919899850. doi: https://doi.org/10.1177/1758835919899850
Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassineti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, Petrelli F. Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a . Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020. PMID: 32010236; PMCID: PMC6974756.
Copy Download .nbib Format: NLM
Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib.

Frontiers in pharmacology

Dalle Fratte C, Guardascione M, De Mattia E, Borsatti E, Boschetto R, Farruggio A, Canzonieri V, Romanato L, Borsatti R, Gagno S, Marangon E, Polano M, Buonadonna A, Toffoli G, Cecchin E.
PMID: 32116712
Front Pharmacol. 2020 Feb 07;11:36. doi: 10.3389/fphar.2020.00036. eCollection 2020.

The standard of care for the first-line treatment of advanced gastrointestinal stromal tumor (GIST) is represented by imatinib, which is given daily at a standard dosage until tumor progression. Resistance to imatinib commonly occurs through the clonal selection of...

Cite
Dalle Fratte C, Guardascione M, De Mattia E, et al. Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. Front Pharmacol. 2020;11:36doi: 10.3389/fphar.2020.00036.
Dalle Fratte, C., Guardascione, M., De Mattia, E., Borsatti, E., Boschetto, R., Farruggio, A., Canzonieri, V., Romanato, L., Borsatti, R., Gagno, S., Marangon, E., Polano, M., Buonadonna, A., Toffoli, G., & Cecchin, E. (2020). Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. Frontiers in pharmacology, 1136. https://doi.org/10.3389/fphar.2020.00036
Dalle Fratte, Chiara, et al. "Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib." Frontiers in pharmacology vol. 11 (2020): 36. doi: https://doi.org/10.3389/fphar.2020.00036
Dalle Fratte C, Guardascione M, De Mattia E, Borsatti E, Boschetto R, Farruggio A, Canzonieri V, Romanato L, Borsatti R, Gagno S, Marangon E, Polano M, Buonadonna A, Toffoli G, Cecchin E. Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. Front Pharmacol. 2020 Feb 07;11:36. doi: 10.3389/fphar.2020.00036. eCollection 2020. PMID: 32116712; PMCID: PMC7019050.
Copy Download .nbib Format: NLM
Erratum to: "Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report" [Cancer Radiother. 23 (2019) 46-9].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Navarria F, Gigante M, Mascarin M, Italia F, Barresi L, Barzan L, Bertola G, Buonadonna A, Canzonieri V, De Paoli A.
PMID: 30962080
Cancer Radiother. 2019 Apr;23(2):173-174. doi: 10.1016/j.canrad.2019.03.007. Epub 2019 Apr 05.

No abstract available.

Cite
Navarria F, Gigante M, Mascarin M, et al. Erratum to: "Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report" [Cancer Radiother. 23 (2019) 46-9]. Cancer Radiother. 2019;23(2):173-174doi: 10.1016/j.canrad.2019.03.007.
Navarria, F., Gigante, M., Mascarin, M., Italia, F., Barresi, L., Barzan, L., Bertola, G., Buonadonna, A., Canzonieri, V., & De Paoli, A. (2019). Erratum to: "Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report" [Cancer Radiother. 23 (2019) 46-9]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 23(2), 173-174. https://doi.org/10.1016/j.canrad.2019.03.007
Navarria, F, et al. "Erratum to: "Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report" [Cancer Radiother. 23 (2019) 46-9]." Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique vol. 23,2 (2019): 173-174. doi: https://doi.org/10.1016/j.canrad.2019.03.007
Navarria F, Gigante M, Mascarin M, Italia F, Barresi L, Barzan L, Bertola G, Buonadonna A, Canzonieri V, De Paoli A. Erratum to: "Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report" [Cancer Radiother. 23 (2019) 46-9]. Cancer Radiother. 2019 Apr;23(2):173-174. doi: 10.1016/j.canrad.2019.03.007. Epub 2019 Apr 05. PMID: 30962080.
Copy Download .nbib Format: NLM
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy.

The World Allergy Organization journal

Severino M, Simioni L, Bonadonna P, Cantone R, Cortellini G, Crescioli S, D'Angelo A, La Rosa L, Macchia D, Martignago I, Massolo A, Reccardini F, Bagnasco D, Passalacqua G.
PMID: 31768218
World Allergy Organ J. 2019 Nov 19;12(12):100086. doi: 10.1016/j.waojou.2019.100086. eCollection 2019 Dec.

INTRODUCTION: It is acknowledged that any claim of efficacy of allergen immunotherapy must be done for each specific product, and this remains true also for venom immunotherapy (VIT). Thus, we evaluated the efficacy and safety of a specific tyrosine-adsorbed...

Cite
Severino M, Simioni L, Bonadonna P, et al. Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy. World Allergy Organ J. 2019;12(12):100086doi: 10.1016/j.waojou.2019.100086.
Severino, M., Simioni, L., Bonadonna, P., Cantone, R., Cortellini, G., Crescioli, S., D'Angelo, A., La Rosa, L., Macchia, D., Martignago, I., Massolo, A., Reccardini, F., Bagnasco, D., & Passalacqua, G. (2019). Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy. The World Allergy Organization journal, 12(12), 100086. https://doi.org/10.1016/j.waojou.2019.100086
Severino, Maurizio, et al. "Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy." The World Allergy Organization journal vol. 12,12 (2019): 100086. doi: https://doi.org/10.1016/j.waojou.2019.100086
Severino M, Simioni L, Bonadonna P, Cantone R, Cortellini G, Crescioli S, D'Angelo A, La Rosa L, Macchia D, Martignago I, Massolo A, Reccardini F, Bagnasco D, Passalacqua G. Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy. World Allergy Organ J. 2019 Nov 19;12(12):100086. doi: 10.1016/j.waojou.2019.100086. eCollection 2019 Dec. PMID: 31768218; PMCID: PMC6872772.
Copy Download .nbib Format: NLM
A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome.

Critical care explorations

Pratt EH, Mausert S, Wilson MD, Emerson LJ, Navuluri N, Pulsipher AM, Brucker A, Green CL, Bonadonna DK, Bryner BS, Rackley CR.
PMID: 34881366
Crit Care Explor. 2021 Dec 03;3(12):e0584. doi: 10.1097/CCE.0000000000000584. eCollection 2021 Dec.

We assessed the effect of implementing a protocol-directed strategy to determine when patients can be liberated from venovenous extracorporeal membrane oxygenation on extracorporeal membrane oxygenation duration, time to initiation of first sweep-off trial, duration of mechanical ventilation, ICU length...

Cite
Pratt EH, Mausert S, Wilson MD, et al. A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome. Crit Care Explor. 2021;3(12):e0584doi: 10.1097/CCE.0000000000000584.
Pratt, E. H., Mausert, S., Wilson, M. D., Emerson, L. J., Navuluri, N., Pulsipher, A. M., Brucker, A., Green, C. L., Bonadonna, D. K., Bryner, B. S., & Rackley, C. R. (2021). A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome. Critical care explorations, 3(12), e0584. https://doi.org/10.1097/CCE.0000000000000584
Pratt, Elias H, et al. "A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome." Critical care explorations vol. 3,12 (2021): e0584. doi: https://doi.org/10.1097/CCE.0000000000000584
Pratt EH, Mausert S, Wilson MD, Emerson LJ, Navuluri N, Pulsipher AM, Brucker A, Green CL, Bonadonna DK, Bryner BS, Rackley CR. A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome. Crit Care Explor. 2021 Dec 03;3(12):e0584. doi: 10.1097/CCE.0000000000000584. eCollection 2021 Dec. PMID: 34881366; PMCID: PMC8647875.
Copy Download .nbib Format: NLM
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.

HemaSphere

Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, Elberink HO, Butterfield JH, George TI, Greiner G, Ustun C, Bonadonna P, Sotlar K, Nilsson G, Jawhar M, Siebenhaar F, Broesby-Olsen S, Yavuz S, Zanotti R, Lange M, Nedoszytko B, Hoermann G, Castells M, Radia DH, Muñoz-Gonzalez JI, Sperr WR, Triggiani M, Kluin-Nelemans HC, Galli SJ, Schwartz LB, Reiter A, Orfao A, Gotlib J, Arock M, Horny HP, Metcalfe DD.
PMID: 34901755
Hemasphere. 2021 Oct 13;5(11):e646. doi: 10.1097/HS9.0000000000000646. eCollection 2021 Nov.

Mastocytosis is a hematologic neoplasm characterized by expansion and focal accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone marrow (BM), spleen, liver, and gastrointestinal tract. The World Health Organization classification divides the disease into...

Cite
Valent P, Akin C, Hartmann K, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021;5(11):e646doi: 10.1097/HS9.0000000000000646.
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., Elberink, H. O., Butterfield, J. H., George, T. I., Greiner, G., Ustun, C., Bonadonna, P., Sotlar, K., Nilsson, G., Jawhar, M., Siebenhaar, F., Broesby-Olsen, S., Yavuz, S., Zanotti, R., Lange, M., Nedoszytko, B., Hoermann, G., Castells, M., Radia, D. H., Muñoz-Gonzalez, J. I., Sperr, W. R., Triggiani, M., Kluin-Nelemans, H. C., Galli, S. J., Schwartz, L. B., Reiter, A., Orfao, A., Gotlib, J., Arock, M., Horny, H. P., & Metcalfe, D. D. (2021). Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 5(11), e646. https://doi.org/10.1097/HS9.0000000000000646
Valent, Peter, et al. "Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal." HemaSphere vol. 5,11 (2021): e646. doi: https://doi.org/10.1097/HS9.0000000000000646
Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, Elberink HO, Butterfield JH, George TI, Greiner G, Ustun C, Bonadonna P, Sotlar K, Nilsson G, Jawhar M, Siebenhaar F, Broesby-Olsen S, Yavuz S, Zanotti R, Lange M, Nedoszytko B, Hoermann G, Castells M, Radia DH, Muñoz-Gonzalez JI, Sperr WR, Triggiani M, Kluin-Nelemans HC, Galli SJ, Schwartz LB, Reiter A, Orfao A, Gotlib J, Arock M, Horny HP, Metcalfe DD. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021 Oct 13;5(11):e646. doi: 10.1097/HS9.0000000000000646. eCollection 2021 Nov. PMID: 34901755; PMCID: PMC8659997.
Copy Download .nbib Format: NLM
A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome.

Critical care explorations

Pratt EH, Mausert S, Wilson MD, Emerson LJ, Navuluri N, Pulsipher AM, Brucker A, Green CL, Bonadonna DK, Bryner BS, Rackley CR.
PMID: 34881366
Crit Care Explor. 2021 Dec 03;3(12):e0584. doi: 10.1097/CCE.0000000000000584. eCollection 2021 Dec.

We assessed the effect of implementing a protocol-directed strategy to determine when patients can be liberated from venovenous extracorporeal membrane oxygenation on extracorporeal membrane oxygenation duration, time to initiation of first sweep-off trial, duration of mechanical ventilation, ICU length...

Cite
Pratt EH, Mausert S, Wilson MD, et al. A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome. Crit Care Explor. 2021;3(12):e0584doi: 10.1097/CCE.0000000000000584.
Pratt, E. H., Mausert, S., Wilson, M. D., Emerson, L. J., Navuluri, N., Pulsipher, A. M., Brucker, A., Green, C. L., Bonadonna, D. K., Bryner, B. S., & Rackley, C. R. (2021). A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome. Critical care explorations, 3(12), e0584. https://doi.org/10.1097/CCE.0000000000000584
Pratt, Elias H, et al. "A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome." Critical care explorations vol. 3,12 (2021): e0584. doi: https://doi.org/10.1097/CCE.0000000000000584
Pratt EH, Mausert S, Wilson MD, Emerson LJ, Navuluri N, Pulsipher AM, Brucker A, Green CL, Bonadonna DK, Bryner BS, Rackley CR. A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome. Crit Care Explor. 2021 Dec 03;3(12):e0584. doi: 10.1097/CCE.0000000000000584. eCollection 2021 Dec. PMID: 34881366; PMCID: PMC8647875.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 126 entries